The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Cytotoxic T-cell based cancer immunotherapy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

Cytotoxic T-cell based cancer immunotherapy is a key innovation area in immuno-oncology

Cytotoxic T-cell cancer therapy is a type of adoptive immunotherapy that makes immune cells to attack cancer cells.  Patient’s T-cells are collected and expanded in the lab. The activated cancer-specific T cells are then reinfused into the patient’s bloodstream and  kill cancer cells by recognising antigens expressed on their surface. Two main types of T-cell transfer therapy are tumour-infiltrating lymphocytes (or TIL) therapy and CAR T-cell therapy.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 180+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of cytotoxic T-cell based cancer immunotherapy.

Key players in cytotoxic T-cell based cancer immunotherapy – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to cytotoxic T-cell based cancer immunotherapy

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Immatics 2033 Unlock Company Profile
OncoTherapy Science 492 Unlock Company Profile
Cellectis 330 Unlock Company Profile
Bristol-Myers Squibb 324 Unlock Company Profile
Iovance Biotherapeutics 298 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 180 Unlock Company Profile
Immunovative Therapies 147 Unlock Company Profile
Fred Hutchinson Cancer Research Center 117 Unlock Company Profile
Gilead Sciences 112 Unlock Company Profile
Autolus 103 Unlock Company Profile
bluebird bio 92 Unlock Company Profile
Seattle Children's Hospital 86 Unlock Company Profile
ImmunityBio 71 Unlock Company Profile
City of Hope 70 Unlock Company Profile
Innovative Cellular Therapeutics 67 Unlock Company Profile
Vaccinex 59 Unlock Company Profile
Fate Therapeutics 58 Unlock Company Profile
Celularity 57 Unlock Company Profile
Sangamo Therapeutics 53 Unlock Company Profile
EpiVax 51 Unlock Company Profile
Takeda Pharmaceutical 47 Unlock Company Profile
United States Of America 47 Unlock Company Profile
AiCuris Anti-infective Cures 46 Unlock Company Profile
ONK Therapeutics 45 Unlock Company Profile
St. Jude Children’s Research Hospital 42 Unlock Company Profile
Io Therapeutics 41 Unlock Company Profile
Eureka Therapeutics 41 Unlock Company Profile
WindMIL Therapeutics 37 Unlock Company Profile
Geneius Biotechnology 37 Unlock Company Profile
Adicet Bio 36 Unlock Company Profile
Green Cross Holdings 36 Unlock Company Profile
TCR2 Therapeutics 35 Unlock Company Profile
Gamida Cell 35 Unlock Company Profile
CRISPR Therapeutics 34 Unlock Company Profile
Editas Medicine 34 Unlock Company Profile
Pfizer 34 Unlock Company Profile
Nuclear Threat Initiative 33 Unlock Company Profile
Massachusetts General Hospital 33 Unlock Company Profile
iCell Gene Therapeutics 33 Unlock Company Profile
Takara Holdings 33 Unlock Company Profile
Gracell Biotechnologies 32 Unlock Company Profile
Allogene Therapeutics 32 Unlock Company Profile
SanBio 32 Unlock Company Profile
TC BioPharm (Holdings) 30 Unlock Company Profile
Otsuka Holdings 30 Unlock Company Profile
BioNTech 29 Unlock Company Profile
PolyBioCept 29 Unlock Company Profile
Magenta Therapeutics 29 Unlock Company Profile
Eutilex 27 Unlock Company Profile
Precision Biosciences 27 Unlock Company Profile

Source: GlobalData Patent Analytics

Immatics NV is a leading patent filer for cytotoxic T-cell based cancer immunotherapy. Its ACTengine programmes are based on genetically engineering a patient’s own, autologous T cells with novel TCRs designed to recognise the cancer target on the tumour. The company has several assets such as IMA203, IMA201 and IMA204. The company is working on TCR-based immunotherapies with an emphasis on treating various solid tumours.

In terms of application diversity, Abclon is the top company, followed by Dragonfly Therapeutics and Marengo Therapeutics. By means of geographic reach, EpiVax holds the top position, followed by Otsuka Holdings and Poseida Therapeutics, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.